Key facts
- Yuimedi’s last known valuation is $16.7M (Dec 2025).
- It has raised $9.3M; the latest was Later Stage VC ($2.6M) in Dec 2025.
- Notable investors include SMBC Venture Capital, Alchemist Accelerator, Nissay Capital, Japan External Trade Organization, Incubate Fund — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Yuimedi
- ·The full record, as it builds
Funding rounds
No funding rounds for Yuimedi are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yuimedi
Developer of a medical data analysis platform intended to support analysis and interoperability. The company's platform automates cleansing, standardization, aggregation, and querying of heterogeneous clinical datasets, supports data governance, semantic mapping, privacy controls, versioning, and API access, enabling healthcare researchers, institutions, and life sciences organizations to integrate dispersed medical data reliably and accelerate evidence generation.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2020
- Employees
- 14
- Website
- yuimedi.com/
- Ownership
- Privately Held (backing)
Yuimedi doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yuimedi shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yuimedi in its N-PORT filings yet. We sweep new filings monthly.